EYECARE: Coronavirus BRIEFING: Crisis Response Tactics U.S. Doctors Reconsider Pfizer's Paxlovid for Lower-Risk COVID Patients By Staff Monday, June 6, 2022 6:03 AM Use of Pfizer Inc's COVID-19 antiviral Paxlovid spiked earlier this month, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time.More quarantine time "is not a crowd-pleaser," Dr. Sandra Kemmerly, an infectious disease specialist at Ochsner Health in New Orleans, told Reuters. "For those people who really aren't at risk ... I would recommend that they not take it."Use of Pfizer's Paxlovid, authorized to treat newly infected, at-risk people in order to prevent severe illness, has soared as infections have risen. More than 162,000 courses were dispensed last week, compared with an average of 33,000 a week since the drug was launched late last year, according to government data. Biden administration officials have pushed for wide use of Paxlovid, which the government purchased and provides for free. Head over to Medscape to read the full story.